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Simple Summary: Epithelial–mesenchymal transition (EMT) is associated with cancer progression. 
Here, we found that two secreted proteins of osteomodulin (OMD) and proline/arginine-rich end 
leucine repeat protein (PRELP) were selectively expressed in bladder umbrella epithelial cells, and 
they were suppressed in bladder cancer. We revealed that OMD−/− or PRELP−/− knockout mice caused 
a breakdown of the umbrella cell layer through weakening cell–cell integrity and the activation of 
partial EMT, which resulted in the formation of early bladder cancer-like structures, while OMD or 
PRELP application to bladder cancer cells inhibited cancer progression through reversing EMT, 
which was mediated by the inhibition of TGF-β and EGF. Our result indicates that OMD and PRELP 
function as tumor-suppressing proteins through inhibiting EMT. OMD and PRELP may be potential 
therapeutic targets in bladder cancer. 
Abstract: Osteomodulin (OMD) and proline/arginine-rich end leucine repeat protein (PRELP) are 
secreted extracellular matrix proteins belonging to the small leucine-rich proteoglycans family. We 
found that OMD and PRELP were specifically expressed in umbrella cells in bladder epithelia, and 
their expression levels were dramatically downregulated in all bladder cancers from very early 
stages and various epithelial cancers. Our in vitro studies including gene expression profiling using 
bladder cancer cell lines revealed that OMD or PRELP application suppressed the cancer 
progression by inhibiting TGF-β and EGF pathways, which reversed epithelial–mesenchymal 
transition (EMT), activated cell–cell adhesion, and inhibited various oncogenic pathways. 
Furthermore, the overexpression of OMD in bladder cancer cells strongly inhibited the anchorage-
independent growth and tumorigenicity in mouse xenograft studies. On the other hand, we found 
that in the bladder epithelia, the knockout mice of OMD and/or PRELP gene caused partial EMT 
and a loss of tight junctions of the umbrella cells and resulted in formation of a bladder carcinoma 
in situ-like structure by spontaneous breakdowns of the umbrella cell layer. Furthermore, the 
ontological analysis of the expression profiling of an OMD knockout mouse bladder demonstrated 
very high similarity with those obtained from human bladder cancers. Our data indicate that OMD 
and PRELP are endogenous inhibitors of cancer initiation and progression by controlling EMT. 
OMD and/or PRELP may have potential for the treatment of bladder cancer. 




Small leucine-rich proteoglycans (SLRPs) are a family of 17 secreted extracellular matrix (ECM) 
proteoglycans [1]. SLRP members function not only as modifiers of ECM organization but also as 
regulators of ligand-induced signaling pathways [1–4]. For example, Tsukushi regulates the Notch, 
Wnt, FGF, BMP4, and Nodal pathways through interactions with extracellular components in a 
context-dependent manner [5–8]. The expression of SLRPs is often altered in tumors. Biglycan, 
lumican, and fibromodulin are overexpressed in various types of cancer, whilst decorin is 
overexpressed in some types of cancer and suppressed in others [9]. High expression levels of 
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lumican are associated with a poorer survival in colorectal tumors, and they are also presented with 
increased metastasis in lung cancers [10]. Conversely, the overexpression of lumican in melanoma 
cells inhibited tumor formation in an animal model [11], whereas low expression levels of lumican 
and decorin are associated with a poorer patient survival in breast tumors and spindle cell 
carcinomas, respectively [12]. Thirty percent of decorin knockout mice develop intestinal tumors [13], 
and decorin/p53 double knockout mice demonstrate an enhanced susceptibility to thymic lymphoma 
[14]. Decorin suppressed squamous cell carcinoma in vitro by binding to EGFR to regulate 
downstream signaling pathways, while it also inhibited tumor formation and metastasis in a 
xenograft model [1,15,16]. However, no mutations or deletions of these genes have been reported so 
far in human cancers. Thus, their relevance to human carcinogenesis remains unclear. 
With the development of epithelial malignancies, major changes occur in the organization of 
ECM, which normally provides the microenvironment for the maintenance of epithelial cell integrity. 
Many oncogenes cannot initiate a tumor if the extracellular microenvironment is normally 
maintained [17]. Moreover, in some cases, breakdown of the extracellular microenvironment by itself 
can trigger tumorigenesis [18]. These studies further demonstrate the importance of ECM proteins in 
cancer development. 
Bladder cancer is one of the most common cancers worldwide, with 549,400 new cases and 
200,000 deaths annually [19]. Our study shows that the two SLRPs or secreted ECM, osteomodulin 
(OMD) and proline/arginine-rich end leucine repeat protein (PRELP) are expressed in bladder and 
critical regulators of bladder cancer initiation and progression via altering cell–cell adhesion, 
probably through the regulation of epithelial–mesenchymal transition (EMT). Our findings can 
explain the mechanism of cancer initiation and can contribute to new therapeutic applications. 
2. Results 
2.1. OMD and PRELP Expression and the Association with the Early Stages of Bladder Cancer 
We analyzed the expression levels of SLRP members in various epithelial cancers including 
bladder cancer using two independent microarray-based expression-profiling databases drawn from 
a worldwide population: Oncomine (Figure 1a,b; Figure S1) and Gene Logic Inc (Figure S2). 
Interestingly, the expression levels of OMD and PRELP are strongly suppressed in the majority of 
epithelial cancer types. 
Next, we performed a detailed expression analysis of 126 bladder cancer samples and 31 normal 
control samples (Figure 1c–f; Table S1). The expression of both OMD and PRELP in tumors was 
drastically lower compared to normal tissues (Figure 1d,f) and declined progressively with cancer 
stage (Figure 1c,1e; Table S1). No associations were found with gender or recurrence status, nor with 
age or tumor size (Table S1). OMD and PRELP were also downregulated in bladder cancer cell lines 
compared to normal bladder tissue (Figure S3a,b). Moderate OMD expression was seen only in the 
non-invasive bladder cell lines RT4 and LHT1376. 
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Figure 1. Expression of osteomodulin (OMD) and proline/arginine-rich end leucine repeat protein 
(PRELP) in cancer (a,b). Microarray analysis of OMD (a) and PRELP (b) expression in human bladder 
cancer samples and normal bladder tissues. (c) Quantitative analysis of OMD expression in bladder 
cancer at different stages by qPCR. (d) Box–whisker plot (median 50% boxed) of (c). Cutoff value 
(dash line) was determined as described in Materials and Methods. (e) Quantitative analysis of PRELP 
expression in bladder cancer at different stages by qPCR. (f) Box–whisker plot of (e). (g) Expression 
analysis of OMD and PRELP in bladder cell lines. Published expression profiling data of MIBC cell 
lines (GSE97768) are re-examined to elucidate the relative expression of OMD and PRELP in 
comparison with known overexpressing genes in bladder cancer; APP, CHEK1, EGFR, ERBB2, and 
TP53 and with housekeeping genes of TUBA1C, TUBB, and TUBD1. (h) Expression analysis of OMD 
and PRELP in bladder tissues samples from patients. Published expression profiling data of non- Non-
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muscle-invasive bladder cancer (NMIBC)(E-MTAB-4321) are re-examined to elucidate the relative 
expression of OMD and PRELP in comparison with APP, CHEK1, EGFR, ERBB2, and TP53 and with 
housekeeping genes of TUBA1C and TUBD1. Details of both (g) and (h) analyses are in Materials and 
Methods. (i) Somatic mutations in human cancer samples that are predicted to generate a loss of 
function of OMD. Detail of cancers is described in Materials and Methods in the section of OMD and 
PRELP Expression Analysis in muscle-invasive bladder cancer (MIBC) cell lines and NMIBC Patient 
Samples. ** indicates p < 0.005. 
To assess the potential role of OMD and PRELP as diagnostic markers, we set cutoff values to 
distinguish tumor samples from normal tissues through calculation of the interquartile range. The 
expression levels of OMD and PRELP in almost all normal bladder tissues were above the cutoff 
value (specificity: 83.9% (OMD) and 90.3% (PRELP)), while expression in the vast majority of tumor 
tissues was below the cutoff (sensitivity: 88.9% (OMD) and 90.5% (PRELP), Table S2). Expression 
levels of OMD and PRELP in the Ta (early) stage of almost all tumor tissues were below the cutoff 
value (sensitivity: 88.9% (OMD) and 88.9% (PRELP), Table S2). When we combined the data for OMD 
and PRELP, the expression of both genes below the cutoff value was found only in tumor samples 
and in none of the normal tissues (specificity 100%). These results show that the expression levels of 
OMD and PRELP genes are powerful markers for the prediction of the presence of urothelial 
carcinomas. The suppression of OMD and PRELP was also observed when we analyzed previously 
published expression profiling data for muscle-invasive bladder cancer (MIBC) and non-muscle-
invasive bladder cancer (NMIBC) (Figure 1g,h) [20,21]. An examination of mutation analysis using 
The Cancer Genome Atlas (TCGA) (Figure 1i) found a total of 3,142,246 somatic substitutions/indels 
were interrogated from 33,096 primary human cancers, and the somatic mutations predicted to 
generate a loss-of-function effect in OMD are summarized in Figure 1i. However, relatively few 
mutations were observed (95 for OMD and 158 for PRELP) (unpublished data). 
2.2. Cell–Cell Adhesion and Cancer Signaling Regulated by OMD and PRELP 
To further assess the role of OMD and PRELP in cancer, we overexpressed or underexpressed 
the two proteins in cultured cells and performed gene expression analysis using microarrays 
(Affimetrix GeneChip® System). The T-Rex-293T system was used to express the genes at a near-
physiological level without causing adverse effects due to their insertion site. To ablate gene 
expression, 5637 bladder cancer cells, expressing OMD and PRELP at a low level, were transfected 
with siRNA constructs for OMD or PRELP. After validating the altered expression of OMD and 
PRELP by RT-PCR, gene expression profiling was performed. 
Figure 2a and b show the numbers of genes that are negatively and positively transcriptionally 
regulated by OMD and/or PRELP, respectively. The genes affected by OMD and PRELP include 
many oncogenes and tumor-suppressor genes such as NF-kB, Ras, and c-Fos. For example, 107 genes 
were activated by both OMD and PRELP overexpression, while 139 genes were suppressed by the 
double-depletion (Figure 2b). These observations indicate that OMD and PRELP have a functional 
redundancy while they also regulate various distinct target genes. 
Next, to elucidate the affected signaling pathways, biological events, and mechanisms, the gene 




NEGfgu7XJjKoC9hVggrFtzQnvxBoCY_wQAvD_BwE). Using the Functional Analysis mode, 
“molecular mechanism of cancer” was identified as one of the most significantly affected biological 
functions and/or diseases in all four conditions of OMD overexpression, OMD depletion, PRELP 
overexpression, and PRELP depletion (Figure 2c; Figure S3c–f). In total, 304 and 388 genes related to 
the “cancer” category are significantly affected by the altered expression of OMD and PRELP, 
including members of the p53 pathway, the NF-kB pathway, the Ras pathway, the RB1 pathway, the 
Jun/Fos pathway, and the Myc pathway (Figure 2d). 
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Our analysis also revealed that both OMD and PRELP strongly influence cell–cell adhesion 
mediated by tight junctions (Figure 2e). Tight junctions are a type of cell–cell junction that binds the 
apical sides of epithelial cells. The breakdown of tight junctions has been proposed as a critical step 
in cancer initiation [22,23]. Tight junction components such as Zonula occlugens-1 (ZO-1) and Nectin 
were transcriptionally activated by OMD or PRELP overexpression, while they were suppressed in 
OMD or PRELP depletion, suggesting that OMD and PRELP have the ability to positively regulate 
tight junctions (Figure 2e). 
 
Figure 2. Gene expression profiling in OMD/PRELP overexpressing or deleted cells. Gene expression 
profiling was performed under seven conditions; OMD overexpression in T-Rex-293T cells, PRELP 
overexpression in T-Rex-293T cells, control T-Rex-293T cells, OMD depletion in the 5637 bladder 
cancer cells, PRELP depletion in the 5637 cells, two controls of the 5637 cells. Details are in Materials 
and Methods. Then, genes with statistical significant changes of mRNA levels have been identified. 
Data were analyzed, and the following figures were made through the use of Ingenuity Pathway 
Analysis (IPA) (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-
analysis). (a) Gene numbers significantly inhibited by OMD overexpression or PRELP overexpression 
but activated by OMD depletion or PRELP depletion. (b) Gene numbers activated by OMD 
overexpression or PRELP overexpression but suppressed by OMD depletion or PRELP depletion. (c) 
Heat map of signaling pathways significantly affected by OMD overexpression. This heat map was 
created using IPA software. Similar heat maps were observed in other three conditions of OMD 
depletion, PRELP overexpression, and PRELP depletion. (d,e) Schematic drawing of the most 
strongly influenced biological events regulated by OMD overexpression. “Molecular Mechanism of 
Cancer” (d) and “Tight junction signaling” (e) category. Both images of (d,e) were created by 
Ingenuity Pathway Analysis according to their rule. This pathway is one of the most strongly 
influenced ones by any of four conditions (OMD overexpression, OMD depletion, PRELP 
overexpression, PRELP depletion). 
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2.3. OMD or PRELP Overexpression in EJ28 Bladder Cancer Cells 
To investigate the roles of OMD and PRELP at the molecular level, we constructed stable cell 
lines that overexpressed OMD, OMD-myc, PRELP, and PRELP-myc using the EJ28 bladder cancer 
cell line, as their endogenous expression is strongly suppressed. 
Under standard cell culture using non-coated culture dish with non-confluent conditions, 
control EJ28 cells had a flattened fibroblast-like shape. In contrast, many OMD overexpressing cells 
had a markedly different round shape with many pin-like extensions (Figure 3a). PRELP 
overexpression also resulted in a change of cell morphology to round cells similar to OMD 
overexpressors together with elongated cells with protruding stress fiber-like filamentous extensions 
(Figure 3a). To evaluate relevant changes in the cytoskeletal structure, we stained for actin and 
tubulin. We found that there are many pin-like actin structures on the surface of the round OMD-
expressing cells, similar to the phenotype induced by cdc42 activation [24]. On the other hand, PRELP 
overexpression resulted in both round cells with pin-like structures and elongated cells with long 
clear actin fibers (Figure 3b). These abnormal morphological changes were also observed with tubulin 
staining (Figure 3c). 
 
Figure 3. Effect of OMD or PRELP overexpression in bladder cancer cell lines. (a) Cell morphology of 
EJ28 bladder cancer cells transfected with OMD, OMD-myc, PRELP, or PRELP-myc constructs, 
observed by differential interference contrast (DIC) microscope. Round cells are indicated as 
arrowheads. (b) Phalloidin staining of the transfected EJ28 cells. Phalloidin (red) and DAPI (blue). 
Pin-like structures of OMD overexpressing cells are phalloidin-positive. PRELP overexpression 
results in clear long actin fiber formation. (c) Anti-tubulin antibody staining. Tubulin (red) and 4’,6-
diamidlino-2-phenylindole (DAPI) (blue). (d,e) Anchorage-independent growth using the soft agar. 
Photos of control, OMD, and PRELP overexpressing colonies formed in the top agar layer (d). 
Quantification of the cell percentage that formed colonies (e). (f) Cell growth in the Matrigel. (g,h) 
Cell migration and invasion assay using the Boyden chamber. Photos of cells that invaded to the 
bottom side of membrane after the addition of fetal bovine serum (FBS) as a chemoattractant (g). 
Quantification of cell migration/invasion in (g,h). (i,j) Transwell co-culture assay to evaluate the effect 
of secreted OMD/PRELP on non-contacting cells. Schematic drawing of the assay system and photos 
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of EJ28 cells cultured at the button chambers (i). Quantification of viable cell density in the bottom 
well by trypan blue staining (j). *, **, *** indicate p < 0.01, p < 0.005, p <0.001, respectively.  
We next analyzed the effect of OMD/PRELP overexpression on cell proliferation and survival. 
First, expression levels of OMD and PRELP in EJ28 cells were analyzed by qRT-PCR (S4a and b) and 
by Western blotting using the myc antibody for myc-tag protein expression (S8n and S8p). OMD and 
OMD-myc cells exhibited reduced proliferation, both in standard proliferation and BrdU 
incorporation assays (Figure S4c,d), while cell cycle analysis by flow cytometry revealed an enhanced 
G1 phase transition (Figure S4e). Finally, OMD and OMD-myc cells presented a small but significant 
increase in apoptosis, as assayed by annexin staining (Figure S4f). The overexpression of OMD, 
OMD-myc, and PRELP resulted in a slight but significant suppression of cell growth with modulation 
of the cell cycle phase distribution. In addition, OMD and PRELP overexpression slightly increased 
apoptosis, although the majority of cells remained non-apoptotic. Overall, we conclude that the 
overexpression of OMD and PRELP proteins results in a subtle but significant suppression of cell 
growth with the modulation of cell cycle phase distribution. 
Anchorage-independent growth is a well-established property of transformed cancer cells. 
Therefore, we examined the effect of OMD or PRELP overexpression on anchorage-independent 
growth (Figure 3d,e). OMD or PRELP-myc overexpression completely abolished colony formation. 
These results indicate that OMD and PRELP suppression might be important for the transition from 
normal epithelial cells to mesenchymal-like cancer cells. Additionally, we tested the cell growth in a 
3D environment using Matrigel to investigate growth under partial anchorage conditions. Control 
EJ28 cells grew well and showed a “spread-like” morphology (Figure 3f), as observed in standard 
cell culture dishes. However, OMD or PRELP overexpressing cells tended to make cell aggregates, 
suggesting that OMD and PRELP may influence cell migration. To address this, we performed the 
Boyden chamber assay with Matrigel-coated transwells. The assay clearly demonstrated that the 
overexpression of OMD or PRELP strongly suppressed cell migration and invasion (Figure 3g,h). The 
effect of OMD and PRELP overexpression on cell migration was also tested in standard 2D conditions 
with the scratch wound assay, where a small inhibition of the wound recovery was observed (Figure 
S4g). Collectively, these results suggest that the two proteins affect colony formation, migration, and 
invasion capabilities of cancer cells in a substrate-dependent manner. 
As OMD and PRELP are secreted proteins, to confirm that the observed effects are mediated by 
the extracellular forms, we performed a co-culture assay, in which EJ28 cells (Cell A) overexpressing 
OMD or PRELP were cultured in the chamber above tester EJ28 cells (Cell B) (Figure 3i). OMD and 
PRELP significantly suppressed the growth of the lower layer of EJ28 tester cells (Figure 3j), as we 
expected. 
2.4. The Relation between OMD or PRELP and Tight Junction Formation 
We examined the status of tight junctions of EJ28 cells using antibodies against occludin (Figure 
4a–i), ZO-1 (Figure 4j–l), and cingulin (Figure 4m–o). In confluent monolayers of the control EJ28 
cells, we observed partial staining at cell–cell interfaces, covering around 40% of the total cell–cell 
surface for occludin, (40% of total cell–cell surface), ZO-1 (46%), and cingulin (30%) (Figure 4p–r). 
This appearance of partial junction staining is found in cancer cell lines (personal communication, 
Karl Matter). Interestingly, the overexpression of OMD resulted in enhanced and continuous 
junctional staining of all three markers, covering almost the whole cell periphery (Figure 4b,h,k,n). 
PRELP overexpression had a similar effect, where tight junction formation was also markedly 
increased compared to the control cells. This enhanced junctional staining was accompanied by a 
reduction of the cytoplasmic staining of the corresponding markers. To further confirm the formation 
of tight junctions, the control EJ28 cells and OMD overexpressing cells were examined by electron 
microscopy. A large number of tight junctions were observed in OMD overexpressing cells (Figure 
4s–u). However, we failed to detect any tight junctions in the control EJ28 cells (Figure 4v,w). 
Cancers 2020, 12, 3362 9 of 26 
 
 
Figure 4. Effect of OMD or PRELP overexpression on tight junction in EJ28 cells. (a–i) Occludin 
antibody staining of OMD or PRELP expressing EJ28 cells; low magnification (a–c), overlaid with 
DAPI (d–f), enlarged (g–i). (j–l) ZO-1 staining. (m–o) Cingulin staining. Scale bar represents 100 μm 
(a–o). (p) Quantification of occluding staining. (q) Quantification of ZO-1 staining. (r) Quantification 
of cingulin staining. (s–w) Electron microscope (EM) analysis of cell-cell junction. OMD expressing 
EJ28 cells (s–u) and wild type (WT) EJ28 cells (v,w). Tight junctions are indicated by arrows. Scale bar 
represents 1 μm (t,u,w) and 0.5 μm (s,v). OMD overexpression strongly activates tight junction 
formation. (x–ff) Antibody staining of confluent monolayer; β-catenin (x–z), E-cadherin (aa–cc), and 
vimentin (dd–ff). Scale bar represents 100 μm (x–ff). *** indicates p < 0.001. 
Subsequently, to determine the effect on adherens junctions, we examined the expression of β-
catenin, E-cadherin, and vimentin. Figure 4x shows that in the control group, many cells have a weak 
β-catenin localization in the nuclei. On the other hand, in OMD or PRELP overexpressing cells, β-
catenin was almost exclusively localized at the plasma membrane, and the strength of the staining 
was much higher than the control (Figure 4x–z). E-cadherin staining was slightly enhanced (Figure 
4aa–cc), indicating that OMD and PRELP activate adherens junctions. To test how OMD and PRELP 
regulated cell–cell adhesion, we examined the expression of vimentin, an EMT marker. The major 
characteristics of epithelial cells are cell polarity, strong cell–cell integrity, and anchorage-dependent 
growth. Cancer initiation in epithelia is always associated with EMT [25,26]. After conversion to 
mesenchymal cells, these cells can grow in an anchorage-independent manner, as observed in almost 
all cancer cells. Figure 4dd–ff shows that vimentin was more localized around or in the nucleus, while 
OMD or PRELP-expressing cells showed a diffuse expression of vimentin in the cytosol. This suggests 
that OMD and PRELP may regulate cell–cell adhesion through EMT. 
2.5. Signal Pathways Regulated by OMD and PRELP 
The gene expression profiling experiment revealed that OMD and PRELP were involved in the 
regulation of various components of several ligand-induced signaling pathways, including the IGF-
1, Wnt, EGF, and TGF-β pathways. We aimed to determine the molecular mechanisms of 
OMD/PRELP activity using EJ28 stable cell lines that overexpress the two proteins. In the expression 
profiling data (Figure 2d), the Akt level was significantly affected by both OMD and PRELP. We 
found that OMD and PRELP overexpression downregulated the phosphorylation of Akt (Figure 5a), 
and OMD overexpression downregulated the phosphorylation of ERK1/2 (Figure 5b). Akt 
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phosphorylation is known to be regulated by the EGF and IGF pathways [27,28]. Figure 5a and b 
show that upon EGF treatment (10 ng/mL), Akt phosphorylation was decreased in the OMD 
overexpressing cells compared to the control. EGF induced the phosphorylation of tyrosine-1068 of 
the EGFR, and this phosphorylation was suppressed by OMD expression (Figure 5b). ERK1/2 
phosphorylation was elevated by exogenous EGF, and this phosphorylation was also suppressed by 
OMD (Figure 5b). Co-immunoprecipitation assays revealed that OMD was bound to the EGFR 
(Figure 5c). Total EGFR protein was reduced in OMD transfected cells (Figure 5d). Inhibition of the 
EGF pathway is known to lead β-catenin localization to the cell membrane [29], which we observed 
in OMD/PRELP activation (Figure 4x). 
IGF activated Akt through the phosphorylation of the IGF-1R; however, OMD overexpression 
did not inhibit the IGF-mediated phosphorylation of Akt (Figure 5e) in our assays. In addition, we 
did not detect any direct interaction of OMD with the IGF receptor (Figure 5f). All the SLRP family 
members previously studied directly interact with TGF-β family members and regulate transcription 
of their targets via the phosphorylation of Smad2 [2]. Indeed, OMD and PRELP directly bound to 
TGF-β protein (Figure 5g) and resulted in Smad2 phosphorylation suppression, particularly in OMD 
(Figure 5h). The effect of OMD and PRELP on EGFR, β-catenin, and Smad2 were quantitated and the 
results are shown in Figure S5. 
 
Figure 5. Mechanism of OMD or PRELP-mediated regulation of tight junction. Various effects of 
OMD and PRELP were examined in vitro using OMD or PRELP stably overexpressing EJ28 bladder 
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cancer cell lines. OMD1 and OMD2 indicate different stable clones. (a) Effect of OMD or PRELP 
overexpression on Akt phosphorylation. (b) Effects of OMD overexpression and EGF application on 
EGF receptor, Akt, and ERK phosphorylation. (c) Interaction between OMD and EGF receptor. (d) 
Effect of OMD or PRELP on the total amount of EGF receptor. (e) Effects of OMD overexpression and 
IGF-1 application on phosphorylation of the IGF receptor, Akt, and ERK. (f) Interaction between the 
OMD and IGF receptors. (g) Binding of OMD or PRELP with TGF-β. (h) Effect of OMD or PRELP on 
Smad2 phosphorylation. (i) Effect of OMD and PRELP on the total levels of β-catenin protein 
expression. (j) Effect of OMD or PRELP on phosphorylation of p38. All original Western blotting data 
are shown in Figure S8. (k) Effect of OMD on cdc42 activity. (l–p) Effect of EGF, IGF-1, and TGF-β 1 
application on tight junction formation of confluent OMD overexpressing EJ28 cell monolayers. 
Occludin staining of normal EJ28 cells (l) and OMD expressing EJ28 cells (m). Effect of 10 ng/mL EGF 
(n), 100 ng/mL IGF-1 (o), or 10 ng/mL TGF-β 1 (p) on occludin staining of EJ28 cells overexpressing 
OMD. Scale bar represents 100 μm. (q) Quantification of occludin-positive cell–cell junctions. (r) TGF-
β, EGF, and Wnt pathways are affected in OMD−/− mouse bladder. Ontological analysis of the 
expression profiling data obtained in Figure 8. (s) Schematic model of OMD/PRELP function. The 
uncropped Western Blot figure in Supplementary Figure S8. **, *** and **** indicate p < 0.005, p < 0.001 
and p < 0.0001, respectively. 
We found that OMD overexpression significantly increased the total amount of β-catenin (Figure 
5i). However, we could not detect a change of Wnt-mediated transcription activity by the TOPFLASH 
assay (unpublished data). Taken together with our finding that OMD causes the translocation of β-
catenin to the plasma membrane (Figure 4x–z), this suggests that the increased β-catenin mainly 
contributes to its adherens junction-related function. 
The downstream segments of ligand-induced signaling pathways are remarkably 
interconnected with each other in context-dependent manners. Thus, we examined two common 
downstream components of the EGF and TGF-β pathways, p38 and cdc42, as the OMD or PRELP 
mediated in vitro phenotypes reported in this paper are similar to those caused by p38 or cdc42 
modulation [30–32]. Moreover, our expression profiling analysis indicated the importance of the 
cdc42 and p38 pathways in this context (Figure 2d). We found that OMD and PRELP overexpression 
increased the phosphorylation of p38 (Figure 5j), and OMD activated cdc42 (Figure 5k). 
Finally, we examined the contribution of OMD-mediated inhibition of pathways to the 
regulation of tight junctions. TGF-β, IGF, and EGF pathways are well known as major pathways to 
regulate EMT and mesenchymal–epithelial transition (MET). OMD overexpressing EJ28 cells were 
treated with either EGF (10 ng/mL), TGF-β (10 ng/mL), or IGF-1 (100 ng/mL) protein, and their effects 
on tight junction formation were assessed. Cellular response was confirmed by analysis of 
phosphorylation of ERK1/2, AKT, and Smad2. Figure 5l–q shows that EGF and TGF-β strongly 
inhibited OMD-induced tight junction formation, while IGF-1 had no effect, suggesting that the 
OMD-mediated regulation of both EGF and TGF-β pathways is important for the regulation of tight 
junctions. In addition, OMD overexpression induced the translocation of β-catenin to the plasma 
membrane (Figure 4x), which was accompanied by an increase in the total expression levels of β-
catenin (Figure 5i). Such effects were previously reported as phenotypes caused by EGF pathway 
inhibition [29]. Later, we will show another gene expression profiling using bladder tissues isolated 
from OMD−/− or PRELP−/− mice (Figure 8). The ontological analysis shows that indeed, OMD/PRELP 
regulate EGF and TGF-β pathways (Figure 5r) 
Our results demonstrate that the OMD-mediated simultaneous regulation of TGF-β and EGF 
pathways is important for the maintenance of cell–cell adhesion (Figure 5s). 
2.6. Tumor Progression in a Mouse Xenograft Model 
In order to examine the in vivo effects of OMD overexpression in cancer development, we 
performed mouse xenograft experiments using stably transformed EJ28 cells. When EJ28 cells were 
grafted in nude mice, the control EJ28 cancer cells grew well, while OMD-expressing EJ28 cells did 
not grow at all (Figure 6a). These observations are in accordance with the decreased anchorage-
independent growth we observed in vitro (Figure 3d–e). Haemotoxylin and Eosin (H&E) staining of 
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tumor sections showed that the density of nuclei was reduced and the nuclear–cytoplasmic ratio was 
increased in OMD-overexpressing samples (Figure 6b–e). Moreover, occludin staining revealed that 
OMD-expressing EJ28 cells have a more organized structure and stronger tight junctions (Figure 6f–
h). Next, we analyzed the ultrastructure of the xenografted cells by electron microscopy. This analysis 
showed that adjacent cells of the control samples intercellular spaces between neighboring cells are 
always visible, and almost no tight junctions can be observed (Figure 6i,j), while the OMD-expressing 
xenografts are in close contact and form multiple tight junctions (Figure 6k,l). These results confirmed 
that OMD/PRELP overexpression enhances cell–cell adhesion and suppresses cancer development in 
vivo. 
 
Figure 6. Mouse xenograft model overexpression of OMD. (a) Xenograft of EJ28 cells stably 
expressing OMD. Tumor volume progression graph. EJ28-WT (n = 5) and EJ28-OMD (n = 5). (b–e) 
Histology of xenografted tissues; H&E staining of control EJ28 cells (b) and EJ28 cells overexpressing 
OMD (c), comparison of the number of nuclei in 100 µm2 of sections (d), comparison of the ratio of 
nucleus vs cytosol. (e) Scale bar represents 100 μm (b,c). (f,g) Occludin staining of control EJ28 tumor 
(f) and OMD overexpressing EJ28 tumor (g). (h) Quantification of occludin staining. The stained 
percentage of cell surfaces was measured. (i) EM of control EJ28 cells. (j) Enlarged from (i). (k) EM of 
OMD-overexpressing EJ28 tumor cells. Scale bar represents 1 μm (i,k). (l) Enlarged from (k). Tight 
junctions are shown with arrows. *** indicates p < 0.001. 
2.7. OMD−/− or PRELP−/− Mice and Tight Junctions between Umbrella Cells 
Next, we established constitutive OMD−/−, PRELP−/−, and OMD−/−/PRELP−/− double knockout mice 
(Figure S6a–d). The knockouts were designed to target exons 2 and 3, resulting in the complete 
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removal of protein coding sequences while knocking in the β-galactosidase gene under the OMD and 
PRELP promoters, respectively. The mice were viable and fertile, and no severe developmental 
defects were observed. OMD and PRELP expression in mice were analyzed by qRT-PCR (Figure 
S6e,f). 
OMD and PRELP were expressed in all organs tested in various levels (Figure S6g and h for 
mouse, i and j for human). To characterize the expression in the bladder, we assayed β-galactosidase 
activity in heterozygous OMD+/−(LacZ) and PRELP+/−(LacZ) mice. We observed β-gal-positive cells only in 
the epithelial layer (Figure S6k,l). A similar pattern was found by the in situ hybridization with the 
OMD or PRELP gene probe (Figure S6m,n). The bladder epithelium contains three cell types: basal 
cells, intermediate cells, and superficial umbrella cells [33]. To identify which cell types express OMD 
or PRELP, bladder sections were co-stained with β-gal and uroplakin-III (umbrella), CK18 (umbrella), 
CK5 (basal), or laminin (basement membrane of epithelium) antibody. In OMD+/− mice, β-gal positive 
cells were always co-localized with a subpopulation of the uroplakin-III and CK18 positive cells, but 
not with CK5 or laminin (Figure S6o–r). We also stained with Ki67 (proliferative) markers (Figure 
S6s), but there was no overlap staining. PRELP showed an expression pattern similar to that of OMD 
(Figure S6t–x). These results indicate that at any one time, the active transcription of OMD and PRELP 
is occurring in a subpopulation of umbrella cells. 
Umbrella cells are connected to each other strongly by tight and adherens junctions [33]. We 
examined the effect of OMD or PRELP deficiency on umbrella cell junctions. Electron microscopy 
images indicated that the apical–lateral interfaces between WT bladder umbrella cells were tightly 
sealed by dense tight junctions (Figure 7a,b). However, strong tight junctions were markedly reduced 
in OMD−/−, PRELP−/−, or the double knockout mice (Figure 7c–e). The reduction at the lateral surface 
was confirmed by immunostaining with the tight junction marker ZO-1. In the WT, ZO-1 staining 
was located at the lateral cell surface (Figure 7f). In OMD−/− or PRELP−/− bladder tissues, the ZO-1 
signal at the lateral cell surface was significantly reduced (Figure 7g–j). Adherens junctions are 
localized in the lateral cell–cell surface between umbrella cells, below the tight junction level. In WT 
mice, the adherens junctions were visible in the basolateral surface of umbrella cells, as marked by E-
cadherin staining (Figure 7k), while in OMD−/−, PRELP−/−, and the double knockout mice, E-cadherin 
was localized in the whole cell surface (Figure 7l–n). This demonstrates that the disruption of tight 
junctions enables E-cadherin to migrate to the apical side of the cell membrane. These observations 
indicate that OMD or PRELP depletion results in the induction of a partial EMT state, which is 
characterized by the loss of tight junctions but not adherens junctions (Figure 7o). 
One of the major functions of tight junctions in the bladder is to form the blood–urine barrier to 
block the leakage of fluids into the bladder [34]. In accordance with this function, deletion of the 
PRELP gene resulted in the formation of clots containing fibrin/fibrinogen in the bladder lumen 
(Figure 7p–q) and the leakage of proteins into the urine (Figure 7r). 
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Figure 7. OMD or PRELP knockout resulted in a loss of tight junctions between bladder umbrella 
cells. (a–e) EM analysis of WT (a,b), OMD−/− (c), PRELP−/− (d), and their double (e) knockout bladders 
at 3 months old. A wide view of WT bladder epithelia, which includes two umbrella cells and an 
intermediate cell. The apical side of the cell–cell surface of umbrella cells (black arrowhead) are 
strongly sealed by dense tight junctions (white arrowheads) (a). Apical side of umbrella cell–cell 
interfaces. Black arrowheads; cell–cell interfaces. White arrowheads; tight junctions (b–e). Scale bar 
represents 200 nm. (f–j) Analysis of ZO-1 staining of a 3-month-old bladder. ZO-1 staining between 
umbrella cells is indicated by white arrowheads (f). Quantification of ZO-1 staining (j). (k–n) E-
cadherin staining of a 3-month-old bladder. (o) Model of cell–cell adhesion in bladder epithelial cells. 
(p) Phosphotungstic acid hematoxylin (PATH) staining of 3-month-old PRELP−/− bladder. PATH 
staining stains fibrin and erythrocytes. (q) Fibrin antibody staining of 3-month-old PRELP−/− bladder. 
(r) Analysis of urinary fibrin. Urine samples were collected from WT and PRELP−/− mice at the 
morning and were tested using Multistix (SIEMENS). * indicates p < 0.01, *, ** indicate p < 0.005, p 
<0.001. 
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2.8. Expression Profiling of OMD−/−, PRELP−/− Bladder Epithelia 
To consolidate our hypothesis that OMD and PRELP contribute to the maintenance of cell–cell 
adhesion and the inhibition of EMT, we performed gene expression profiling by RNA-seq using 
isolated bladder epithelia from WT mice (n = 3), OMD−/− (n = 5), and PRELP−/− (n = 3). Similarly to our 
previous gene expression analysis data (Figure 2), 148 genes were commonly affected both in OMD−/− 
and in PRELP−/− (Figure 8a), indicating their partial functional redundancy. 
These genes include components of cell–cell adhesion and EMT (Figure 8b). Ontological analysis 
using the IPA showed that EMT-related events such as “Regulation of the Epithelial–Mesenchymal 
Transition Pathway” (OMD−/−, z = 6.26, PRELP−/−, z = 1.31) (Figure 8c–e) were significantly affected in 
both OMD−/− and PRELP−/− bladder epithelia. Additionally, cell–cell adhesion-related pathways, 
which is a consequence of EMT, such as “Tight Junction Signaling”, and “Germ Cell–Sertoli Cell 
Junction Signaling”, were significantly affected both in OMD−/− and PRELP−/−, confirming their 
involvement in the maintenance of the epithelial junctional barrier. 
The ontological analysis also revealed that many cancer-related pathways are more strongly 
affected (Figure S7a,b), even to a higher extend compared to the gene expression profiling performed 
in cell lines (Figure 2). Many oncogenes and tumor-suppressor genes are strongly affected (Figure 
S7c). Figure S6d shows the schematic diagram of “Molecular Mechanisms of Cancer” pathway, 
affected in OMD−/− (z = 15.2), indicating that a majority of cancer-related regulators such as NF-kB, 
p53, myc, Ras, c-Jun/c-Fos, TGF-β R1/2, and RB are significantly affected. Since the host mouse strain 
C57BL/6J is not known to hold tumorigenic mutations in the above proteins, these data confirm that 
in parallel with their ability to regulate EMT and cell–cell integrity, OMD and PRELP have the ability 
to influence cancer-related activities. Furthermore, in order to know how deeply the OMD 
suppression in bladder cancer contributes to the properties of bladder cancer, we searched already 
deposited publicly available expression profiling datasets that showed similarities with that of 
OMD−/− retina. This analysis revealed that many cancer-related public datasets showed strong 
similarity with our OMD−/− dataset. In particular, as shown in Figure 8e, both bladder transitional cell 
carcinoma and bladder carcinoma showed the strong similarity [35,36]. This result demonstrates the 
significant contribution of OMD suppression in human bladder cancer initiation and/or progression. 
In addition, we examined the similarity between the OMD−/− and PRELP−/− expression profiling 
datasets using the Analysis Match software. Figure 8e shows the high similarity between OMD−/− 
and PRELP−/−, supporting the results in Figure 8a–d. 
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Figure 8. Expression profiling of OMD−/−, PRELP−/− mouse bladder epithelia. Expression profiling was 
performed using OMD−/−, PRELP−/− mouse bladder epithelia. Data were analyzed, and the following 
figures were made through the use of IPA (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis). (a) Significantly 
affected gene numbers, including both up and downregulated. (b) Expression of genes related to cell–
cell adhesion and EMT. (c,d) Significantly affected cell adhesion-related pathways in OMD−/− (c) and 
PRELP−/− (d). The same pathways are connected by arrows. (e) Similarity of expression profiling data. 
Using Analysis Match software (Ingenuity Pathway Analysis, IPA, Qiagen), we examined the 
similarity of expression profiling data of OMD−/− retina with the already deposited publicly available 
expression profiling dataset and those of PRELP−/− retina. OMD−/− retina data showed high similarity 
with PRELP−/− retina. The public database search revealed that bladder cancer-related datasets 
showed high similarity in all categories. CP; canonical pathways, UR; upstream regulators, CN; causal 
networks, DE; downstream effectors. (f) Schematic drawing of “Regulation of the EMT pathway” in 
OMD−/− vs. WT. Drawing was slightly modified from the original of “Regulation of the EMT 
Pathway”. This image was created by Ingenuity Pathway Analysis according to their rule. 
2.9. Breakdown of the Umbrella Cell Layer in OMD−/− and PRELP−/− Mice 
We made 10 µm paraffin section series from whole bladder specimens of WT, OMD−/−, PRELP−/−, 
and double knockout mice and examined the fine structure of the urothelium. In the WT mice, 
bladder umbrella cells form a clear single epithelial layer at the apical side of the urothelium and 
function as a barrier to the toxic bladder fluid (Figure 9a–c). In contrast, all of the bladder tissue 
samples from OMD−/−, PRELP−/−, and the double knockout mice showed points of 
breakdown/dysplasia of the urothelium (Figure 9d–l). We here termed these histological structures 
as “epithelial bursts”. Furthermore, histological observation and bladder marker staining showed 
that the spread cells of the epithelial bursts originated from umbrella cells expressing uroplakin-III 
(Figure 9m–n), while their number was significantly increased in OMD−/− or PRELP−/− mice (Figure 
9o). Of note, no obvious abnormalities were seen in the basal and intermediate cell layers (Figure 9p). 
To investigate whether the epithelial bursts are associated with aberrant cell proliferation, we 
performed immunohistochemical analysis using the Ki67 proliferation marker. There are few Ki67-
positive cells in the WT bladder urothelium, and their number is only slightly increased in the OMD−/− 
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and the double knockout samples, suggesting that the epithelial bursts do not result from increased 
proliferation (Figure 9q). 
In humans, carcinoma in situ (CIS) appears histologically as a flat dysplasia of umbrella cells 
and is recognized as an early sign of malignant bladder cancer. However, an epithelial burst-type 
dysplasia, as seen in the OMD−/− and PRELP−/− mouse bladders, has not been recognized. The luminal 
mouse bladder is consistently covered by convex mucosal folds, while the human bladder surface is 
relatively flat or slightly concave. During our histological analysis, we observed a simple flat 
dysplasia of umbrella cells in the concave areas of mouse bladder as in human CIS (Figure 9r–t), 
suggesting that the structural difference of dysplasia might result from the different urothelium 
structure: convex vs. concave. To address this, we developed a mathematical simulation to visualize 
the direction of epithelial layer breakdown through the calculation of the forces created on convex 
and concave structures (Figure 9u). The model demonstrated that in a convex structure, the basal side 
of the epithelial layer was sealed, and the epithelial cells tended to escape to the apical side, similar 
to an epithelial burst. On the other hand, in a concave structure, the apical side was sealed, and the 
dysplasia cells tended to move under the epithelial layer. Supporting our analysis, Messal et al. has 
recently reported that a mechanical tension model for tissue curvature can instruct the direction of 
cancer morphogenesis [37]. These model-based analyses suggest that OMD and/or PRELP deletion 
can result in a defect in maintenance of the umbrella cell layer, as observed in human bladder CIS. 
 
Figure 9. OMD−/−, PRELP−/−, and their double knockout mice spontaneously initiate bladder papillary 
cancer. (a–l) 3-month-old bladder of WT (a–c), OMD−/− (d–f), PRELP−/− (g–i), and their double knockout 
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(j–l). A low magnification and two high magnification images are shown in order. Epithelial bursts 
are indicated as arrows. Some enlarged areas are indicated as boxes in low-magnification images. 
Scale bar represents 500 μm (a,d,g,j) and 100 μm (b,c,e,f,h,i,k,l). (m–o) Uroplakin III antibody staining 
of an epithelial burst of OMD−/−. Uroplakin staining (m), overlaid view of uroplakin III and DAPI (n). 
Scale bar represents 50 μm (m–n). Quantification of epithelial burst number per bladder; WT (n = 7), 
OMD−/− (n = 7), PRELP−/− (n = 6), OMD−/−, PRELP−/− (n = 3) (o). In quantification, we examined six to 
seven 10 µm slices from each bladder. Each slice was separated around 200 µm in the bladder, and 
these slices covered the whole bladder except their edges. (p) Laminin antibody staining of WT and 
OMD−/− bladders. (q) Ki-67 staining positive cells in bladder. (r–t) Carcinoma in situ (CIS)-like 
structures in OMD−/− (r) and PRELP−/− (s,t). (u) Computational models for the mouse and human 
epithelial dysplasia. Conditions of models (u-i). Calculated forces between cells (u-ii). Direction of 
dysplasia (u-iii). Epithelial burst-like dysplasia and carcinoma in situ-like dysplasia (u-iv). *** 
indicates p < 0.001. 
2.10. Some PRELP−/− Mice Spontaneously Initiate Bladder Papillary Cancer 
On analysis of bladders from OMD−/−, PRELP−/−, and the double knockout mice, we found that 
OMD−/−, PRELP−/−, and double KO bladders showed a slightly increased number of mucosal folds 
with multiple branches (Figure 10a,b). Interestingly, in one-third of the PRELP−/− and double 
knockout mice but not in OMD−/− mice, the bladder developed abnormal urothelia with hyperplasia, 
resulting in a pattern of papillary growth on a normal muscularis (Figure 10c,e in WT, d, f–o in 
PRELP). This phenotype seen in some PRELP−/− bladders is similar to some types of human bladder 
papillary cancer (https://www.proteinatlase.org/learn/dictionary/pathology/urothelial + cancer). 
We observed various stages of papillary cancer progression such as mucosal folds with multiple 
branches (Figure 10g), partially fused mucosal folds (Figure 10h), and completely fused mucosal folds 
(Figure 10i,j). The process of clot formation was also observed, including small aggregates of 
proteinaceous material secreted from umbrella cells (Figure 10i), larger aggregates in which clumps 
of cells were embedded (Figure 10k,l), and large acellular clots covered with a single layer of cells 
(Figure 10m). We observed early signs of cancer invasions into the underlying muscularis (Figure 
10n,o). 
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Figure 10. PRELP knockout mice spontaneously initiate early stages of bladder cancer. (a) H&E-
stained section showing a branched mucosal fold. (b) Number of mucosal folds with multiple 
branches. In each bladder, we have examined two sections in the medial region of bladder. (c) H&E-
stained section of a WT mouse bladder at 3 months of age. (d) Bladder papillary cancer in PRELP−/− at 
3 months. Scale bar represents 500 μm (c,d). The bladder lumen is almost completely filled by mucosal 
folds with multiple branches and fused mucosal folds. Clots formation is observed. Enlarged regions 
in the following panels are indicated by the dotted boxes. (e) WT bladder muscularis (Mus) and 
epithelial tissue (Epi). (f) PRELP−/− bladder muscularis. (g) Mucosal fold with multiple branches. (h) 
Partially fused mucosal folds with multiple branches. (i) Fused mucosal folds. The arrow points 
secretion of materials to lumen. (j) Fused mucosal folds. Deposited material is enriched in fused folds 
(arrow). (k) Separation of epithelial cells with sticky material. (l) Aggregation of separated cells with 
clot materials. (m) The clot is covered by a layer of cells. (n) T1 stage bladder cancer in PRELP−/− at 3 
months. (o) Epithelial papillary cancer integration into muscularis (arrows). ** and *** indicate p < 
0.005, and p < 0.001, respectively. 
3. Discussion 
3.1. ECM Proteins and Cancer Initiation 
OMD and PRELP are secreted ECM proteins, belonging to the Class II SLRP subfamily [38–40]. 
SLRP family members were originally identified as abundant proteins within the ECM of cartilage, 
connecting tissues and differentiating osteoblasts [41–43]. ECM proteins of the tumor 
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microenvironment play important roles in many aspects of cancer initiation and progression [44]. 
One member of the SLRP family, decorin expression, decreases on the malignant transformation of 
tumor cells. Thirty percent (30%) of decorin knockout mice developed spontaneous intestinal tumors 
[13]. On the other hand, in an inflammation murine model, decorin is upregulated in endothelial cells 
and facilitates the downregulation of tight junctions [45]. This suggests that inflammation may affect 
OMD and PRELP function. 
Here, we have demonstrated that OMD and PRELP function to maintain epithelial cell–cell 
integrity in urothelial cells through the inhibition of partial EMT. At epithelial cancer initiation, EMT 
is required, while MET is observed at cancer metastasis. Recent comprehensive expression profiling 
analyses in bladder and other epithelial cancers have revealed a novel concept of partial EMT [46–
49]. The typical partial EMT state is the loss of tight junctions without affecting adherens junctions 
[48]. This is particularly important for understanding cancer initiation. In bladder cancer, a loss of E-
cadherin expression is used as a marker of advanced bladder cancer, suggesting that the partial EMT 
state might be associated with early-stage bladder cancer. The tight junctions between umbrella cells 
in OMD−/− and PRELP−/− mice disappeared, while adherens junctions were maintained, indicating a 
typical partial EMT state. The loss of tight junctions resulted in disruption of the apical–basal polarity 
of umbrella cells, which is demonstrated by uniform E-cadherin staining around umbrella cells. 
Moreover, the partial EMT state we observed is susceptible for breakdown of the umbrella-cell layer, 
which might be related to cancer initiation. Collectively, our findings might be the first demonstration 
of partial EMT state and associated bladder cancer initiation in mice. 
3.2. OMD and PRELP and NMIBC Initiation 
OMD−/− or PRELP−/− mice showed many breakdown sites in the umbrella-cell layer, and one-third 
of PRELP−/− developed large-scale papillary cancer without muscle invasion. A large region of 
chromosome 9q, including the OMD gene, is deleted in half of NMIBC cases [50]. The deletion is 
associated with the initiation of NMIBC [51]. PTCH and TSC1 were proposed to be the critical tumor-
suppressor genes in 9q deletions [52,53], but this hypothesis is controversial [54]. Rather, with the 
present study, we propose OMD as a novel 9q-residing tumor-suppressor gene involved in cancer 
bladder initiation. 
NMIBC is clinically classified as Ta, T1, or CIS. CIS is proposed to originate from umbrella cells 
because the cells in CIS are positive to umbrella cell markers such as CK20 [55]. Recent comprehensive 
expression profiling analysis classified NMIBC into three classes. Among these, Class 2 has the 
expression of CIS type markers, and Class 2 is defined based on the expression of EMT marker genes 
[20]. OMD−/− or PRELP−/− showed two types of breakdown of the umbrella layer: epithelial bursts and 
CIS-like structures. Our mathematical model indicates that the difference between the two 
breakdowns reflects the structural differences of the epithelia. We propose that umbrella-layer 
breakdown mediated by the loss of OMD and PRELP may initiate CIS. Some bladder cancers are 
thought to originate from the umbrella cells [51], because selective overexpression of a mutant H-Ras 
in umbrella cells resulted in low-grade papillary tumors [56–58]. 
Additionally, PRELP−/− mice tended to form protein clots, including fibrin, in the bladder. The 
fibrin/fibrinogen degradation products in human urine samples have been used as a bladder cancer 
marker [59]. The leakage of fibrin is regulated by the blood–urine barrier in bladder epithelial cells. 
This suggests that damage to the blood urine barrier is associated with bladder cancer initiation and 
that PRELP may have the ability to regulate the blood–urine barrier. Interestingly, we have found 
that in OMD−/− and PRELP−/− mice, umbrella cells are connected to each other by adherens junctions. 
It is known that the loss of E-cadherin is a marker of conversion from benign to malignant bladder 
cancer. Thus, double knockout of OMD/PRELP and E-cadherin may reveal the process of malignant 
cancer initiation. 
3.3. EMT/MET Regulated by OMD and PRELP 
During malignant transformation, cancer cells have acquired mesenchymal-like characteristics 
such as anoikis resistance and invade adjacent tissues. Our results showed that OMD or PRELP 
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overexpression in bladder cancer cells resulted in an increase of epithelial-like properties such as tight 
junction induction and adherens junction activation as well as a change of EMT markers. A cardinal 
feature of cancer is the ability for anchorage-independent growth, which changes the properties of 
cell–cell and cell–matrix adhesion conferred at EMT. 
Umbrella cells secrete signaling proteins such as EGF and TGF-β [60]. The concept that OMD or 
PRELP mediated the inhibitory activity of TGF-β and EGF pathways could be important for the 
regulation of EMT/MET, because the TGF-β/Smad2 pathway is the biggest common target of all SLRP 
family members [2] and is a well-known regulator of EMT/MET [46]. In addition, EGF is known as a 
major regulator of EMT/MET [46] and is one of the most established targets of cancer treatment [61]. 
Previously, we reported that the simultaneous regulation of Xnr2, FGF, and BMP pathways by 
Tsukushi, another SLRP member, had an increased synergistic effect compared to the single 
regulation of each pathway alone [6]. 
OMD and PRELP are selectively expressed in the ciliary body of the retina and in ependymal 
cells in the brain (paper in preparation) that are characterized by strong tight junctions forming the 
blood–CSF barrier. The expression of many components of tight junctions is associated with 
tumorigenesis [62]. However, so far, there is no report showing that the knockout of any tight junction 
component by itself can spontaneously lead to tumor formation, although, hyperplasia of the gastric 
epithelium has been observed in an occludin knockout model [63]. This suggests that the loss of tight 
junctions alone is not sufficient to initiate bladder cancer. TGF-β and EGF pathways are involved in 
the regulation of many cancer-associated signaling pathways, suggesting that in addition to the loss 
of tight junctions in an OMD−/− or PRELP−/− bladder, further regulation of TGF-β and EGF downstream 
signaling components might be required for cancer initiation. Of note, one limitation of our study is 
that although the TGF-β-flag protein bound with OMDmyc and PRELPmyc proteins directly, the 
binding affinities of secreted TGF-β to the OMD and PRELP is unknown; therefore, further studies 
are required. 
3.4. The Similarity and Difference between OMD and PRELP 
Both OMD and PRELP were downregulated, especially in bladder cancer. Our results indicated 
that although OMD and PRELP share considerable amount of signal pathways, there are some 
differences in the observed phenotypes: branching, proliferation, bladder cancer progression, and 
protein expression. Functional difference between OMD and PRELP may be associated with certain 
cancer phenotypes. This indicates that they would play a redundant and non-redundant function in 
bladder cancer. 
3.5. Diagnostic and Therapeutic Potential of OMD and PRELP in Bladder Cancer 
OMD and PRELP are expressed in normal human epithelia. However, in many epithelial 
cancers, they are strongly downregulated. Particularly, their expression in the bladder is drastically 
reduced even in very early stages of cancer. This potentially means that it is possible to classify a 
patient’s clinical state based solely on their OMD and PRELP expression status from early-stage 
cancers. So far, several diagnostic markers of bladder cancer have been used in clinics such as BTA-
Stat (sensitivity 50–70%, specificity 67–78%) and fibrin degradation products (FDP) (sensitivity 52–
68.4%, specificity 79.6–91%) [64]. With our findings, we show that the assessment of OMD and PRELP 
expression status can be used as a novel, more sensitive, criterion in assessing the initiation and 
progression of bladder cancer. We also observed a similar evaluation in renal cell carcinoma and 
retinoblastoma (paper in preparation), proposing their diagnostic potential in various epithelial 
cancers, possibly through using new technology such as quench bodies to detect loss-of-function 
regions [65]. This study demonstrates that the functions of OMD and PRELP are partially redundant 
in the regulation of both cell–cell integrity and cancer initiation/progression, and they are potentially 
important, especially for bladder cell therapeutics. 
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4. Materials and Methods 
Materials and Methods are described in the Supplementary Materials and Methods. The 
accession number for the raw and processed data of microarray and RNA-seq data from OMD and 
PRELP knockdown experiments reported in this paper is GEO: GSE63955 and GSE144295. Other data 
supporting our findings can be found either in this article or in the supplementary materials. Please 
contact the corresponding author for all “unpublished data” and “paper in preparation” requests. 
The research protocol was reviewed and approved by the Ethical Committee of Addenbrooke’s 
Hospital, Cambridgeshire Local Research Ethics Committee (No. 03/018). 
5. Conclusions 
In this study, we demonstrated that two SLRP proteins, OMD and PRELP, are novel activators 
of the cell–cell integrity by inhibiting EMT through the simultaneous inhibition of TGF-β and EGF 
signaling. The downregulation of OMD and PRELP expression was observed in all of the cancers we 
analyzed, including bladder cancer. We showed that in association with a change of EMT states, 
OMD or PRELP suppression in mice resulted in an initiation of bladder cancer, while the activation 
of OMD or PRELP inhibited bladder cancer progression in vitro and in vivo. We propose that OMD 
and PRELP-mediated regulation of EMT is important for the initiation of human bladder cancer. 
Supplementary Materials: The following are available online at www.mdpi.com/2072-6694/12/11/3362/s1, 
Figure S1: Microarray analysis of OMD and PRELP expression in various cancers and normal tissues; Figure S2: 
Expression analysis of OMD and PRELP in various human cancers using Gene Logic Inc. Figure S3: OMD and 
PRELP expression analysis in various cancer cells and ontological analysis of expression profiling data; Figure 
S4: Effect of OMD or PRELP on cell properties under standard cell culture conditions; Figure S5: Quantification 
of OMD and PRELP effects; Figure S6: PRELP is expressed in subpopulation of bladder umbrella epithelial cells; 
Figure S7: The ontological analysis in OMD−/− and PRELP−/− bladder epithelia; Figure S8: Original Western 
Blotting images used in Figure 5.; Table S1: Statistical analysis of OMD and PRELP expression levels in clinical 
bladder tissues; Table S2: Relationship between OMD and PRELP expression levels and carcinogenesis; Table 
S3: Primer sequences for quantitative RT-PCR.  
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